

Publications of the Week

Continuous but Not Intermittent Theta Burst Stimulation Decreases Striatal Dopamine Release and Cortical Excitability

First Author: Lucero Aceves-Serrano | Senior Author: Doris Doudet (pictured)
Experimental Neurology | UBC



Dopamine modulation is thought to underpin some of the therapeutic effects associated with repetitive transcranial magnetic stimulation (rTMS). However, patient studies have failed to demonstrate consistent changes in the dopamine system *in vivo* after a therapeutic course of rTMS. The authors evaluated acute and chronic changes in striatal dopamine release elicited by a clinically relevant course of theta burst or sham stimulation using [¹¹C]raclopride in healthy non-human primates. **Abstract**

Ansellone J, a Potent *In Vitro* and *Ex Vivo* HIV-1 Latency Reversal Agent Isolated from a *Phorbas* sp. Marine Sponge

First Author: Meng Wang | Senior Author: Raymond Andersen (pictured)
Journal of Natural Products | UBC and SFU




Five new minor sesterterpenoids, ansellones H, I, J, and K, and phorone C, have been isolated from a *Phorbas* sp. marine sponge collected in BC. Their structures have been elucidated by detailed analysis of NMR and mass spectrometry data. Ansellone J and phorone C are potent *in vitro* HIV-1 latency reversal agents that are more potent than the reference compound and control protein kinase C activator prostratin. **Abstract**

[View All Publications](#)

Awards

UBC Medicine Researchers Awarded over \$2.5 Million from Canada's Stem Cell Network

UBC Faculty of Medicine



Researchers from UBC's Faculty of Medicine have been awarded over \$2.5 million from Canada's Stem Cell Network to advance six regenerative medicine research projects and clinical trials. Dr. Nika Shakiba (pictured), Assistant Professor of Biomedical Engineering, will elucidate the competitive advantage of aberrant pluripotent stem cells in suspension bioprocesses. **Read More**

Congratulations to the Winners of the 2021 CAN-CIHR-INMHA Brain Star Awards!

Canadian Association for Neuroscience



The Canadian Association for Neuroscience (CAN) and the Canadian Institutes of Health's Institute of Neurosciences, Mental Health, and Addiction (CIHR-INMHA) are proud to announce the winners of the 2021 Brain Star Awards. Dr. Jessica Rosin (pictured) showed that specific immune cells in the hypothalamus respond to maternal stress and influence nearby neural stem cells, but only in male mice. **Read More**

[View All Featured Awards](#) | [View Monthly Award Summaries](#)

Local News

BC Researchers Launching Clinical Trial for First Genetically Engineered Stem Cell-Based Therapy for Type 1 Diabetes

UBC Faculty of Medicine



Researchers from the UBC Faculty of Medicine and Vancouver Coastal Health have received \$1 million from Canada's Stem Cell Network to conduct research and a clinical trial for one of the world's first genetically engineered cell replacement therapies for type 1 diabetes. The novel investigative treatment, developed by CRISPR Therapeutics and ViaCyte, is designed to enable type 1 diabetes patients to produce insulin through a small medical implant that contains pancreatic cells derived from CRISPR gene-edited stem cells. **Read More**

CBR Alumni Journeys: Dr. Katharine Sedivy-Haley Is Exploring the Breadth of Science Policy

Centre for Blood Research (CBR)



A non-linear path in life is sometimes key to opening many unexpected opportunities. This is the case for Dr. Katharine (Kate) Sedivy-Haley (pictured), a PhD alumnus of the Centre for Blood Research. Dr. Sedivy-Haley recently graduated from the PhD program for Microbiology and Immunology at UBC. She is currently a Policy Advisor at Innovation, Science, and Economic Development Canada. **Read More**

Algeron Pharmaceuticals Announces Last Patient Treated in Phase II Study of IPF and Chronic Cough

GlobeNewswire



Algeron Pharmaceuticals, a clinical stage pharmaceutical development company, has announced that the last patient has completed the treatment period in its Phase II proof of concept study of NP-120 for idiopathic pulmonary fibrosis (IPF) and chronic cough. "We are pleased to be coming closer to this value inflection point in our Phase II clinical trial for IPF and chronic cough, both debilitating conditions with limited treatment options," said Christopher Moreau, CEO of Algeron. **Read More**

Predicting Patient Response to Cancer Immunotherapy with Neoantigens

Canada's Michael Smith Genome Sciences Centre



Cancer immunotherapy is a form of treatment that uses the body's immune system to identify and attack tumour cells to stop cancer from spreading. While concluding that neoantigen counts from noncoding DNA are not informative for predicting patient response to immune checkpoint inhibitors, a study by Tammy Lau (pictured) and a team in Dr. Aly Karsan's lab suggests that characterization of these peptides could significantly expand options for personalized cancer treatment. **Read More**

Burnaby's Kardium Closing In on Commercialization

Business in Vancouver



Kevin Chaplin, CEO of Kardium, can now take a short drive to St. Paul's Hospital to see how the first clinical trials in North America are unfolding for Kardium's devices treating atrial fibrillation (an irregular heartbeat). With Conformité Européenne certification secured in the EU, clinical trials underway in Canada, and testing set to begin early next year at 20 clinical sites in the US, Kardium's commercialization journey is in full ramp-up mode after 15 years of development. **Read More**

[View All Local News](#) | [Submit an Article](#)

Interesting Articles

Canada's Stem Cell Network Makes Its Single Largest Investment in Regenerative Medicine Research

Stem Cell Network



Canada's Stem Cell Network (SCN) has announced \$19.5 million for 32 stem cell and regenerative medicine research projects and clinical trials. This investment is SCN's largest funding injection into the sector, made possible through increased funding by the Government of Canada in 2021. With in-kind and cash support from 34 partner organizations valued at \$22.4 million, this investment allows Canada's regenerative medicine research community to harness a total of \$42 million for research activities and clinical trials over the next three years. **Read More**

[View All Interesting Articles](#) | [Submit an Article](#)

Upcoming Events in Vancouver

- May 17 2:00 PM **Building an Online Academic Presence** Online
- May 18 8:30 AM **2022 BCRegMed 6th Annual Symposium** UBC
- May 20 11:00 AM **Cancer Nanomedicine: Using Gold Nanoparticles to Overcome Radiotherapy Challenges** Online
- May 25 9:00 AM **Neuroscience and Neurotechnology Seminar Series** Online
- May 27 8:10 am **PathDay 2022** Holiday Inn, 711 West Broadway

[View All Events](#) | [Submit an Event](#)

STEMCELL Jobs in Vancouver

- Associate Director/Director, Product Management Life Science Products** STEMCELL Technologies
- Scientist** STEMCELL Technologies
- Program Coordinator** STEMCELL Technologies
- Process Development Associate, Chemistry** STEMCELL Technologies
- Research Technologist, Bioengineering** STEMCELL Technologies

[View 119 Other STEMCELL Jobs](#)

Other Science Jobs in Vancouver

- Buyer** AdCellera
- Curriculum Development and Instructor, Animal Cell Culture Course** BCIT
- Research Assistant 2, Cancer Imaging** BC Cancer
- Scientific Communications Specialist** Aspect Biosystems
- mRNA Production Specialist** NanoVation Therapeutics

[View 41 Other Science Jobs](#) | [Submit a Job](#)

Networking & Conference Toolkit

Follow These Tips to Prepare for Your Next Conference



[ACCESS NOW](#)

Submit your articles and events by reaching out to us at info@scienceinvancouver.com.

BROUGHT TO YOU BY



STEMCELL Technologies
Products | Services

STEMCELL Science News
Free Weekly Updates on Your Field

The Stem Cell Podcast
Interviews and Updates on Stem Cell Science